The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis

Multiple Sclerosis

Cryptococcal meningoencephalitis in an IgG₂-deficient patient with multiple sclerosis on fingolimod therapy for more than five years - case report

BMC Neurol.

Wienemann T, Müller AK, MacKenzie C, Bielor C, Weyers V, Aktas O, Hartung HP, Kremer D

doi: 10.1186/s12883-020-01741-0.

Further Publications NeurologyFurther Publications Psychiatry

Severe disease activity in a patient with multiple sclerosis after daclizumab discontinuation

Mult Scler Relat Disord.

Martinelli V, Dalla Costa G, Sangalli F, Colombo B, Robotti M, Moiola L, Comi G

doi: 10.1016/j.msard.2018.11.034.

Multiple Sclerosis

Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report

BMC Neurol.

Patti F, Leone C, Zappia M

doi: 10.1186/s12883-015-0512-0.

Multiple Sclerosis

Secukinumab for patients with plaque psoriasis affected by multiple sclerosis. A mini-review with a representative case report

J Eur Acad Dermatol Venereol.

Venturini M, Zanca A, Venturuzzo A, Filippini M, Frassi M, Tincani A, Calzavara-Pinton PG

doi: 10.1111/jdv.16035.

Multiple Sclerosis

Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment

Mult Scler.

Graf J, Ringelstein M, Lepka K, Schaller J, Quack H, Hartung HP, Aktas O, Albrecht P

doi: 10.1177/1352458518771276.

Further Publications NeurologyFurther Publications Psychiatry

Cognitive behavioral therapy for insomnia: A meta-analysis of long-term effects in controlled studies

Sleep Med Rev.

van der Zweerde T, Bisdounis L, Kyle SD, Lancee J, van Straten A

doi: 10.1016/j.smrv.2019.08.002.

Multiple Sclerosis

Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report

Mult Scler Relat Disord.

Lapucci C, Gualandi F, Mikulska M, Palmeri S, Mancardi G, Uccelli A, Laroni A

doi: 10.1016/j.msard.2018.09.006.

Multiple Sclerosis

Efficacy of Natalizumab in Intermediate Uveitis Related to Multiple Sclerosis: A Case Report

doi: 10.1055/s-0043-124756.

Aging and Cognitive FunctionsMultiple Sclerosis

Progressive visual function impairment as the predominant symptom of the transition phase to secondary progressive multiple sclerosis: A case report

Mult Scler Relat Disord.

Giordano A, Colombo B, Spinelli EG, Gelibter S, Guerrieri S, Leocani L, Comi G, Martinelli V

doi: 10.1016/j.msard.2018.06.011.

Related content

Cryptococcal meningoencephalitis in an IgG2-deficient patient with multiple sclerosis on fingolimod therapy for more than five years - case report

Severe disease activity in a patient with multiple sclerosis after daclizumab discontinuation

Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report

Secukinumab for patients with plaque psoriasis affected by multiple sclerosis. A mini-review with a representative case report

Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment

Cognitive behavioral therapy for insomnia: A meta-analysis of long-term effects in controlled studies

Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report

Efficacy of Natalizumab in Intermediate Uveitis Related to Multiple Sclerosis: A Case Report

Progressive visual function impairment as the predominant symptom of the transition phase to secondary progressive multiple sclerosis: A case report

Cryptococcal meningoencephalitis in an IgG₂-deficient patient with multiple sclerosis on fingolimod therapy for more than five years - case report